116 related articles for article (PubMed ID: 38881003)
21. Assessment of HER-2/neu, с-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas.
Buchynska LG; Brieieva OV; Iurchenko NP
Exp Oncol; 2019 Jun; 41(2):138-143. PubMed ID: 31262163
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.
Sato K; Qian J; Slezak JM; Lieber MM; Bostwick DG; Bergstralh EJ; Jenkins RB
J Natl Cancer Inst; 1999 Sep; 91(18):1574-80. PubMed ID: 10491435
[TBL] [Abstract][Full Text] [Related]
23. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW
Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962
[TBL] [Abstract][Full Text] [Related]
24. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.
Shimada H; Stram DO; Chatten J; Joshi VV; Hachitanda Y; Brodeur GM; Lukens JN; Matthay KK; Seeger RC
J Natl Cancer Inst; 1995 Oct; 87(19):1470-6. PubMed ID: 7674334
[TBL] [Abstract][Full Text] [Related]
25. Pathologic stage of prostatic ductal adenocarcinoma at radical prostatectomy: effect of percentage of the ductal component and associated grade of acinar adenocarcinoma.
Amin A; Epstein JI
Am J Surg Pathol; 2011 Apr; 35(4):615-9. PubMed ID: 21383610
[TBL] [Abstract][Full Text] [Related]
26. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
27.
Barry KH; Mohanty K; Erickson PA; Wang D; Shi J; Rose G; Cellini A; Clark K; Ambulos N; Yin J; Yan L; Poulin M; Meyer A; Zhang Y; Bentzen SM; Burke A; Hussain A; Berndt SI
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374332
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of hTERC and C-Myc genes amplification in a group of Egyptian patients with cancer cervix.
Eid MM; Nossair HM; Ismael MT; Amira G; Hosney MM; Abdul Rahman R
Gulf J Oncolog; 2011 Jul; (10):18-26. PubMed ID: 21724525
[TBL] [Abstract][Full Text] [Related]
29. c-myc oncogene copy number in squamous carcinoma of the head and neck.
Haughey BH; von Hoff DD; Windle BE; Wahl GM; Mock PM
Am J Otolaryngol; 1992; 13(3):168-71. PubMed ID: 1626617
[TBL] [Abstract][Full Text] [Related]
30. c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization.
Sauter G; Carroll P; Moch H; Kallioniemi A; Kerschmann R; Narayan P; Mihatsch MJ; Waldman FM
Am J Pathol; 1995 May; 146(5):1131-9. PubMed ID: 7747807
[TBL] [Abstract][Full Text] [Related]
31. MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study.
Shon W; Sukov WR; Jenkins SM; Folpe AL
Mod Pathol; 2014 Apr; 27(4):509-15. PubMed ID: 24091875
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.
Hawksworth D; Ravindranath L; Chen Y; Furusato B; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):311-5. PubMed ID: 20820186
[TBL] [Abstract][Full Text] [Related]
33. MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors.
Singhi AD; Cimino-Mathews A; Jenkins RB; Lan F; Fink SR; Nassar H; Vang R; Fetting JH; Hicks J; Sukumar S; De Marzo AM; Argani P
Mod Pathol; 2012 Mar; 25(3):378-87. PubMed ID: 22056952
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
Ma C; Downes M; Jain R; Ientilucci M; Fleshner N; Perlis N; van der Kwast T
Prostate; 2022 Feb; 82(3):345-351. PubMed ID: 34878188
[TBL] [Abstract][Full Text] [Related]
35. Does prostate acinar adenocarcinoma with Gleason Score 3+3=6 have the potential to metastasize?
Montironi R; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Santoni M; Briganti A; Montorsi F; Cheng L
Diagn Pathol; 2014 Oct; 9():190. PubMed ID: 25326076
[TBL] [Abstract][Full Text] [Related]
36. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
37. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM
Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985
[TBL] [Abstract][Full Text] [Related]
38. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.
Gurel B; Iwata T; Koh CM; Jenkins RB; Lan F; Van Dang C; Hicks JL; Morgan J; Cornish TC; Sutcliffe S; Isaacs WB; Luo J; De Marzo AM
Mod Pathol; 2008 Sep; 21(9):1156-67. PubMed ID: 18567993
[TBL] [Abstract][Full Text] [Related]
39. Over-expression and amplification of the c-myc gene in human urothelial carcinoma.
Christoph F; Schmidt B; Schmitz-Dräger BJ; Schulz WA
Int J Cancer; 1999 Apr; 84(2):169-73. PubMed ID: 10096250
[TBL] [Abstract][Full Text] [Related]
40. Relationship of NKX3.1 and MYC gene copy number ratio and DNA hypomethylation to prostate carcinoma stage.
Kindich R; Florl AR; Kamradt J; Lehmann J; Müller M; Wullich B; Schulz WA
Eur Urol; 2006 Jan; 49(1):169-75; discussion 175. PubMed ID: 16310933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
